The FDA has accepted a new drug application seeking approval for zanzalintinib (XL092) in combination with atezolizumab (Tecentriq) for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, and, if RAS wild type, anti-EGFR therapy.1
The regulatory agency has assigned a Prescription Drug User Fee Act target action date of December 3, 2026.
Topline Data From the STELLAR Trial
- Among patients with previously treated mCRC in the ITT population, zanzalintinib plus atezolizumab showed an OS benefit over regorafenib. The median OS was 10.9 months vs 9.4 months, respectively (HR, 0.80; 95% CI, 0.69-0.93; P = .0045).
- Consistent OS and PFS benefit was observed across most key subgroups, and a numerically greater OS benefit was seen in patients without liver metastases (HR, 0.79; 95% CI, 0.61-1.03), though these data were immature.
- The most common AEs observed with the combination included diarrhea (50%), hypertension (34%), fatigue (33%), nausea (31%), and decreased appetite (30%).
The NDA is supported by data from the phase 3 STELLAR-303 trial (NCT05425940), which met its dual primary end point of significantly improved overall survival (OS) with zanzalintinib plus atezolizumab vs regorafenib (Stivarga) in the intention-to-treat (ITT) population of patients with previously treated colorectal cancer.
Of note, OS outcomes in patients without active liver metastases, the trial’s other primary end point, were immature at the data cutoff. According to Exelixis, the drug’s developer, the trial is proceeding to the planned final analysis for this end point; these data are expected to read out mid-2026.
“We are encouraged by this meaningful progress toward addressing the needs of patients with previously treated mCRC, for whom effective therapies have been limited and treatment outcomes remain poor,” Dana T. Aftab, PhD, executive vice president of research and development at Exelixis, stated in a news release. “Zanzalintinib has the potential to become an important advancement in a challenging treatment landscape, and, if approved, zanzalintinib in combination with atezolizumab would provide a novel mechanism of action for patients with previously treated mCRC. We are deeply grateful to the patients, caregivers, and investigators contributing to the clinical research in support of this application, and we look forward to collaborating with the FDA during the review process for our first NDA for zanzalintinib.”
What Was the Design of the STELLAR Trial?
The global, randomized, open-label trial enrolled patients aged 18 or older with confirmed metastatic adenocarcinoma of the colon or rectum who did not have documented microsatellite instability-high or mismatch repair–deficient status.2 Patients were also required to have disease that radiographically progressed on, or was refractory or intolerant to, prior standard-of-care treatment, including fluoropyrimidine plus irinotecan and oxaliplatin with or without an anti-VEGF antibody, an anti-EGFR antibody, and a BRAF inhibitor.